by admin | Aug 1, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
image Caption: Sensory interneurons (with nuclei in red) derived from mouse stem cells. Credit: UCLA Broad Stem Cell Research Center Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a...
by admin | Jul 30, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
image caption: Microscope image of pancreatic tissue, magnification 25X. Shows Islets of Langerhans (lightly stained, pink areas – composed of alpha and beta cells, endocrine tissue), and exocrine tissue (darker, surrounding tissue, secretes digestive enzymes)....
by admin | Jul 29, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions, Video
Doctors turn to stem cell treatment to heal the youngest hearts Almost one out of 100 babies are born with a heart defect each year in the United States. Many of these babies will need surgery within weeks of birth, followed by more surgeries throughout their lives....
by admin | Jul 28, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
Image Caption: New research into factors that control the life and death of hair follicle cells could help people with baldness, as well as wound healing. Credit: Helpaeatcontu/Wikimedia by Jules Bernstein, University of California – Riverside A single chemical...
by admin | Jul 27, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
By Fraiser Kansteiner – Fierce Pharma Just a few weeks after Cognate BioServices moved to beef up its cell and gene therapy manufacturing, the company has attracted a buyer eager to tap that expertise. Charles River Laboratories agreed to throw down $875 million...
by admin | Jul 26, 2022 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
By Max Bayer – Fierce Pharma Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The all-cash deal announced Monday...
